A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants

被引：16

作者：

Sharma, Hitt ^{[1
]}

Yadav, Sangita ^{[2
,3
]}

Lalwani, Sanjay ^{[4
]}

Gupta, Vijay ^{[5
]}

Kapre, Subhash ^{[1
]}

Jadhav, Suresh ^{[1
]}

Chakravarty, Anita ^{[6
]}

Parekh, Sameer ^{[1
]}

Palkar, Sonali ^{[4
]}

机构：

[1] Serum Inst India Ltd, Pune 411028, Maharashtra, India

[2] Maulana Azad Med Coll, Dept Pediat, New Delhi, India

[3] Associated LNJP Hosp, New Delhi, India

[4] Bharati Vidyapeeth Univ, Dept Pediat, Med Coll & Hosp, Pune, Maharashtra, India

[5] Dr Ram Manohar Lohia Hosp, Dept Pediat & Neonatol, New Delhi, India

[6] Maulana Azad Med Coll, Dept Microbiol, New Delhi, India

来源：

VACCINE | 2011年 / 29卷 / 13期

关键词：

Liquid pentavalent vaccine; Combination vaccine; Immunogenicity; Safety; India; EVENT FOLLOWING IMMUNIZATION; CASE-DEFINITION; DATA-COLLECTION; INJECTION SITE; GUIDELINES; SAFETY; POLYSACCHARIDE; BURDEN;

D O I：

10.1016/j.vaccine.2011.01.054

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunogenicity and tolerability of two liquid pentavalent vaccines, Pentavac (R) (new vaccine), and Easyfive (R) (available in the market) was assessed in a multicentre study in India. In all, 484 infants aged 6-8 weeks were enrolled, and their blood samples were assessed prior to the first dose and one month after the third dose. A 100% seroprotection rate was achieved with both vaccines' antigens, except pertussis for which the response was 95% and 96%, respectively, for the two vaccines. A diary-based recording of adverse events showed that the two most common events were pain at the injection site and restricted limb movements and were less frequent (p < 0.001) among the recipients of the new vaccine. The new vaccine meets all criteria of childhood vaccination. Its low reactogenicity and low cost are valid reasons to recommend this vaccine for general use. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：2359 / 2364

页数：6

共 50 条

[31] Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects
Lawrence, Jody
He, Su
Martin, Jason
Schoedel, Florian
Ciarlet, Max
Murray, Alexander V.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2247 - 2254
[32] Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study
Fan, Renfeng
Huang, Xiaoyuan
Nian, Xuanxuan
Ou, Zhiqiang
Zhou, Jian
Zhang, Jiayou
Zeng, Peiyu
Zhao, Wei
Deng, Jinglong
Chen, Wei
Chen, Shaomin
Duan, Kai
Chen, Yingshi
Li, Xinguo
Zhang, Jikai
Yang, Xiaoming
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01) : 1 - 9
[33] A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process
Marshall, Gary S.
Senders, Shelly D.
Shepard, Julie
Twiggs, Jerry D.
Gardner, Julie
Hille, Darcy
Hartzel, Jonathan
Valenzuela, Rowan
Stek, Jon E.
Helmond, Frans A.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (08) : 2188 - 2196
[34] Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study
Nolan, Terry
Bhusal, Chiranjiwi
Hoberman, Alejandro
Llapur, Conrado J.
Voloshyna, Olga
Fink, Ezekiel
Gentile, Angela
Wallace, Garry
Richmond, Peter C.
Domachowske, Joseph B.
Mzolo, Thembile
Lattanzi, Maria
Toneatto, Daniela
BOOST Study Grp, Adebayo
CLINICAL INFECTIOUS DISEASES, 2025,
[35] Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study
Dbaibo, Ghassan
Tinoco Favila, Juan Carlos
Traskine, Magali
Jastorff, Archana
Van der Wielen, Marie
VACCINE, 2018, 36 (28) : 4102 - 4111
[36] Safety and immunogenicity of fully liquid DTaP5-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP3-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: A phase III, modified double-blind, randomized, controlled, multicenter study
Berner, Reinhard
Boisnard, Florence
Thomas, Stephane
Mwawasi, Grace
Reynolds, Donna
VACCINE, 2012, 30 (35) : 5270 - 5277
[37] Immunogenicity, Safety, and Tolerability of Two Trivalent Subunit Inactivated Influenza Vaccines: A Phase III, Observer-Blind, Randomized, Controlled Multicenter Study
Tregnaghi, Miguel W.
Stamboulian, Daniel
Carina Vanadia, Paula
Pablo Tregnaghi, Jorge
Calvari, Miriam
Fragapane, Elena
Casula, Daniela
Pellegrini, Michele
Groth, Nicola
VIRAL IMMUNOLOGY, 2012, 25 (03) : 216 - 225
[38] Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Preterm European Infants: A Randomized Phase IIIb Study
Omenaca, Felix
Sarlangue, Jean
Szenborn, Leszek
Nogueira, Marta
Suryakiran, Pemmaraju V.
Smolenov, Igor V.
Han, Htay H.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (05) : 487 - 493
[39] A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants
Martinon-Torres, Federico
Gimenez-Sanchez, Francisco
Bernaola-Iturbe, Enrique
Diez-Domingo, Javier
Jiang, Qin
Perez, John L.
VACCINE, 2014, 32 (40) : 5206 - 5211
[40] A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults
Sheldon, Eric
Kitchin, Nicholas
Peng, Yahong
Eiden, Joseph
Gruber, William
Johnson, Erik
Jansen, Kathrin U.
Pride, Michael W.
Pedneault, Louise
VACCINE, 2016, 34 (18) : 2082 - 2091

← 1 2 3 4 5 →